Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660

Benzinga · 4d ago
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.